Canada Life’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Canada Life’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	-$7K	–	2459
2022 Q1	$7K	Hold	5	–	–	﹤0.01%	2456
2021 Q4	$13K	Hold	5	–	–	﹤0.01%	2426
2021 Q3	$94K	Hold	5	–	–	﹤0.01%	2062
2021 Q2	$54K	Hold	5	–	–	﹤0.01%	2248
2021 Q1	$37K	Hold	5	–	–	﹤0.01%	2390
2020 Q4	$28K	Hold	5	–	–	﹤0.01%	2478
2020 Q3	$51K	Hold	5	–	–	﹤0.01%	2175
2020 Q2	$47K	Buy	+5	New	+$45.8K	﹤0.01%	2235

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Canada Life's IRLA Position: Q2 2022 in Review

Canada Life sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 5 shares — an estimated $7K sold.

Canada Life first reported a position in IRLA in Q2 2020 and held it in 8 quarters. The position peaked at $94K in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

Canada Life reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Canada Life sold 5 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $7K.
Canada Life first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Canada Life's IRulya Therapeutics Inc. Common Stock position peaked at $94K in Q3 2021.
66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on Canada Life's 13F filing for Q2 2022, filed 9 Aug 2022.